Lineage Cell Therapeutics, Inc. Long-Lived Assets
Lineage Cell Therapeutics, Inc. (LCTX) had Long-Lived Assets of $5.67 million as of 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Notes
us-gaap:NoncurrentAssets · last filed 2023-03-09
- 2022-12-31: Long-Lived Assets $5.67M.
- 2021-12-31: Long-Lived Assets $4.87M.
- 2020-12-31: Long-Lived Assets $5.63M.
- 2019-12-31: Long-Lived Assets $8.18M.
| Period end | Long-Lived Assets |
|---|---|
| 2022-12-31 | $5.67M 10-K · filed 2023-03-09 |
| 2021-12-31 | $4.87M 10-K · filed 2023-03-09 |
| 2020-12-31 | $5.63M 10-K · filed 2022-03-10 |
| 2019-12-31 | $8.18M 10-K · filed 2021-03-11 |
| 2018-12-31 | $5.83M 10-K · filed 2020-03-12 |
| 2017-12-31 | $5.53M 10-K · filed 2019-03-14 |
| 2016-12-31 | $5.53M 10-K · filed 2018-03-15 |
| 2015-12-31 | $7.54M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |